Equillium, Inc. EQ
Equillium, Inc. (Nasdaq: EQ) is a GI/hepatology drug developer. Its lead program, EQ504, is in Pre-clinical for ulcerative colitis and other GI diseases (inflammatory lung diseases as expansion).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EQ504 (aryl hydrocarbon receptor modulator) | ulcerative colitis / GI diseases | small molecule | Pre-clinical |
| EQ302 (bispecific IL-15/IL-21 inhibitor, oral) | celiac disease / inflammatory bowel disease | protein/peptide | Pre-clinical |
Recent results and decisions
- Oct 26, 2026started Equillium dosed the first patient in a single ascending dose trial of EQ504 in Australia.
The Company announced that it had dosed the first patient in a single ascending dose trial of EQ504 in Australia on October 26, 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.